Changes in Hong Kong stocks | Collumbotai Biotech (06990) rose more than 4% in the morning, and the application for clinical trial of the novel dual-load ADC drug SKB565 was approved

The Zhitong Finance App learned that Colunbotai Biotech (06990) rose more than 4% in the morning. As of press release, it had risen 3.8% to HK$510.5, with a turnover of HK$95.924 million.

According to the news, Collumbotai Biotech recently issued an announcement. The company received a clinical trial notice from the Drug Evaluation Center of the State Drug Administration and approved the new drug clinical trial application for its novel dual-load ADC drug SKB565 to treat advanced solid tumors. This is the company's first “dual-load” antibody conjugate drug to enter the clinical stage. The approval of SKB565 marks a key step in the company's “ADC+IO” integrated development strategy.